



C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study

Tong Liu^{1,2,3} | Qingsong Zhang⁴ | Chunhua Song⁵ | Sarah Tan Siyin⁶ |
 Shuohua Chen⁷ | Qi Zhang^{1,2,3} | Mengmeng Song^{1,2,3}  | Liying Cao⁸ |
 Hanping Shi^{1,2,3} 

¹Department of Gastrointestinal Surgery/
 Clinical Nutrition, Capital Medical University
 Affiliated Beijing Shijitan Hospital, Beijing,
 China

²Beijing International Science and Technology
 Cooperation Base for Cancer Metabolism and
 Nutrition, Beijing, China

³Key Laboratory of Cancer FSMP for State
 Market Regulation, Beijing, China

⁴Department of General Surgery,
 Kailuan General Hospital, Tangshan, China

⁵Department of Epidemiology and Statistics,
 College of Public Health, Zhengzhou
 University, Zhengzhou, Henan, China

⁶Department of General Surgery, Beijing
 Children's Hospital, National Center for
 Children's Health, Beijing, China

⁷Department of Cardiology, Kailuan General
 Hospital, Tangshan, China

⁸Department of Hepatological Surgery,
 Kailuan General Hospital, Tangshan, China

Correspondence

Hanping Shi, Department of Gastrointestinal
 Surgery/Clinical Nutrition, Beijing Shijitan
 Hospital, Capital Medical University,
 Beijing 100038, China.

Email: shihp@ccmu.edu.cn

Liying Cao, Department of Hepatological
 Surgery, Kailuan General Hospital, Tangshan,
 China, 063000.

Email: lyc176700@mail.ccmu.edu.cn

Funding information

Beijing Municipal Science and Technology
 Commission, Grant/Award Number:

Abstract

A single CRP measurement is insufficient to examine the association of long-term patterns of CRP concentration with cancer risk. We prospectively examined the relationship between CRP trajectory patterns and new-onset cancers among 52 276 participants. Latent mixture modeling was used to identify CRP trajectories. Cox proportional hazards regression models were used to evaluate the association between CRP trajectory patterns and the risk of overall and specific-site cancer. Four CRP trajectory patterns were identified: low-stable pattern (n = 43 258), moderate-increasing pattern (n = 2591), increasing-decreasing pattern (n = 2068) and elevated-decreasing pattern (n = 4359). Relative to the low-stable pattern, the moderate-increasing trajectory pattern was associated with an elevated risk of overall, lung, breast, leukemia, bladder, stomach, colorectal, liver, gallbladder or extrahepatic bile duct cancer and leukemia. Participants in the increasing-decreasing trajectory pattern were associated with an elevated risk of overall, lung, breast, bladder, pancreatic and liver cancer. The increasing-decreasing trajectory pattern was also associated with decreased risk of colorectal cancer in the multivariate analyses. Elevated-decreasing trajectory pattern was associated with increased risk of leukemia and decreased risk of esophageal and colorectal cancer. CRP trajectories play an important role in the occurrence of cancers, especially in the lung, breast, bladder, stomach, colorectal, liver, gallbladder and extrahepatic bile duct cancer and leukemia.

KEYWORDS

cancer, C-reactive protein, prospective, risk, trajectory

What's new?

Chronic inflammation is closely associated with cancers. However, most previous studies used a single measurement of C-reactive protein (CRP) level at baseline. This prospective, population-

Abbreviations: ALT, alanine aminotransferase; ANOVA, one-way analysis of variance; BIC, Bayesian information criterion; BMI, body mass index; CRC, colorectal cancer; CRP, C-reactive protein; FBG, fasting blood glucose; HBsAg, hepatitis B surface antigen; hs-CRP, high sensitivity CRP; TBil, total bilirubin; TC, total cholesterol; TG, triglyceride.

Tong Liu, Qingsong Zhang and Chunhua Song contributed equally to this article and share the first author.

Hanping Shi and Liying Cao contributed equally to this article and share the corresponding author.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

SCW2018-06; National Key Research and Development Program, Grant/Award Number: 2017YFC1309200

based cohort study with a two-year follow-up frequency provides a novel perception of the potential association between longitudinal CRP trajectory patterns and cancer risk. The results show that CRP trajectories play an important role in the occurrence of cancers, especially in the lung, breast, bladder, stomach, colorectal, liver, gallbladder or extrahepatic bile duct cancer and leukemia. The decreasing CRP trajectory pattern is associated with decreased esophageal and colorectal cancer risk.

1 | INTRODUCTION

Cancer is the first or second leading cause of premature death in 134 of 183 countries, and it ranks third or fourth in 45 of the remaining countries.¹ About one-third of deaths from non-communicable diseases are due to cancer.¹ The morbidity and mortality rates vary across countries due to different prevalence of key risk factors, as well as the impact of preventive methods, screening and therapeutic interventions.^{2,3} Robust scientific evidence is essential for understanding its cause and prevention. In addition to some recognized factors like smoking,⁴ drinking,⁵ obesity,⁶ nutrition,⁷ family history of cancer, infectious disease⁸ and environmental factors,⁹ chronic inflammation has been demonstrated to be closely associated with cancers.^{10,11} Cancer-associated inflammation is known as the seventh hallmark of cancer, associated with the six generally recognized hallmarks of cancer: self-sufficient growth signals, evasion of apoptosis, insensitivity to antigrowth signals, unlimited replicative potential, sustained angiogenesis and metastasis.¹⁰

C-reactive protein (CRP) is a classic acute-phase protein that responds to inflammation, infection and tissue damage, and is the most widely used biomarker of inflammation.^{12,13} Recently, epidemiologic studies have demonstrated an association of elevated levels of circulating high sensitivity CRP (hs-CRP), CRP measured by a high-sensitivity assay which can accurately detect low-grade inflammatory state, with an increased risk of incident cancers.¹⁴⁻¹⁶ However, results from previous studies were based on a single measurement of CRP level at baseline which may yield a certain degree of variability during the follow-up period and lead to misclassification of the participants.

No prospective study has used multiple CRP measurements to examine the association of long-term patterns of CRP concentration with subsequent cancer risk. Kailuan study is an ongoing, prospective, population-based cohort study with follow-up conducted every 2 years. Repeated CRP measurements can offer us a great opportunity to ascertain the association between CRP trajectory patterns and the risk of incident cancers.

2 | METHODS

2.1 | Study population

Data was taken from the Kailuan cohort study, which was designed to explore the risk factors for common chronic diseases. The detailed study design and procedures were described previously.¹⁷

All 155 418 Kailuan Corporation employees (including retirees) were invited to participate in baseline physical examinations at Kailuan General Hospital and its 10 affiliated institutions between July 2006 and October 2007. A total of 101 510 individuals (65.3%) ranging in age from 18 to 98 years, with 81 110 males and 20 400 females, accepted and were enrolled after receiving written informed consent. All participants underwent health examinations including questionnaire assessments, clinical examinations and laboratory tests at baseline examination (2006-2007), and underwent follow-up examinations with the same examinations conducted every 2 years.

In the current study, CRP trajectories were developed from 2006 to 2010 to predict cancer risk from 2010 to 2019. In other words, the study was restricted to the population who participated in the examinations in 2006, 2008 and 2010 and had their plasma CRP measurements taken biennially. Participants were excluded if they: (1) failed to take 2008 and/or 2010 examinations; (2) had missing information of plasma CRP during 2006-2010; (3) lacked measurements of relevant confounders including age, sex, total cholesterol (TC, in mmol/L), triglyceride (TG, in mmol/L), body mass index (BMI, in kg/m²), alanine aminotransferase (ALT, in u/L), total bilirubin (TBil, in umol/L), fasting blood glucose (FBG, in mmol/L), hepatitis B surface antigen (HBsAg), dietary salt intake, marital status, sedentary lifestyle, educational background, tobacco consumption, alcohol drinking, physical exercise, family history of cancer, liver cirrhosis, fatty liver, gallstone disease, gallbladder polyp, diabetes mellitus and hypertension; and (4) had a history of cancer at baseline or were diagnosed with cancer during 2006 to 2010 (trajectory patterns). A total of 52 276 individuals were left in the final analyses and scheduled a follow-up (Figure 1).

2.2 | Assessment of plasma CRP

After an overnight fasting period (at least 8 hours), blood samples were obtained from the antecubital vein in EDTA tubes for each individual. The blood was further centrifuged for 10 minutes at 3000 rotations per minute at 25°C. Plasma was separated and stored at -80°C until laboratory determinations were performed. CRP was measured using a high-sensitivity nephelometry assay (Cias Latex CRP-H, Kanto Chemical Co. Inc., Tokyo, Japan) and the lower limit of detection is 0.1 mg/L. The intra- and interassay coefficient of variation for CRP measurement were 6.53% and 4.78%, respectively. Plasma CRP and other blood variables were all analyzed at the central laboratory of the Kailuan Hospital using an autoanalyzer (Hitachi 747; Hitachi).

TABLE 1 Baseline characteristics of the participants according to hs-CRP trajectory patterns

Variables	Hs-CRP trajectory patterns				P-value
	Low-stable	Moderate-increasing	Increasing-decreasing	Elevated-decreasing	
n (%)	43 258	2591	2068	4359	
Age (year)	48.40 ± 11.62	49.99 ± 11.97	52.70 ± 12.15	55.17 ± 11.07	<.0001
Male (%)	32 915 (76.09)	2072 (79.97)	1509 (72.97)	3195 (73.30)	<.0001
Marital status (%)					<.0001
Never	734 (1.70)	36 (1.39)	24 (1.16)	28 (0.64)	
Married	40 637 (93.94)	2337 (90.20)	1871 (90.48)	3397 (77.95)	
Divorced	382 (0.88)	18 (0.69)	17 (0.82)	32 (0.73)	
Widowed	580 (1.34)	45 (1.74)	34 (1.64)	103 (2.36)	
Remarried	925 (2.14)	155 (5.98)	122 (5.90)	799 (18.32)	
Educational background (%)					<.0001
Never	276 (0.64)	19 (0.73)	19 (0.92)	40 (0.91)	
Primary school	2954 (6.83)	174 (6.72)	176 (8.51)	406 (9.30)	
Middle school	29 542 (68.29)	1823 (70.36)	1436 (69.43)	2781 (63.80)	
High school	6801 (15.72)	313 (12.08)	270 (13.06)	470 (10.80)	
College graduate or above	3685 (8.52)	262 (10.11)	167 (8.08)	662 (15.19)	
TC (%)					<.0001
<4.50 mmol/L	14 712 (34.01)	741 (28.60)	564 (27.28)	1473 (33.80)	
4.50-5.32 mmol/L	14 197 (32.82)	862 (33.27)	700 (33.85)	1451 (33.29)	
>5.32 mmol/L	14 349 (33.17)	988 (38.13)	804 (37.83)	1435 (32.91)	
TG (%)					<.0001
<1.02 mmol/L	14 970 (34.61)	703 (27.14)	546 (26.41)	1409 (32.33)	
1.02-1.65 mmol/L	14 302 (33.06)	773 (29.84)	640 (30.95)	1375 (31.55)	
>1.65 mmol/L	13 986 (33.58)	1115 (43.02)	882 (42.64)	1575 (36.12)	
ALT (%)					.0095
<15.00 u/L	15 538 (35.92)	908 (35.05)	729 (35.26)	1649 (37.83)	
15.00-22.00 u/L	13 193 (30.50)	735 (28.37)	627 (30.32)	1328 (30.47)	
>22.00 u/L	14 527 (33.07)	948 (36.58)	712 (34.42)	1382 (31.70)	
TBil (%)					<.0001
<10.70 umol/L	13 079 (30.23)	986 (38.06)	705 (34.09)	2320 (53.23)	
10.70-14.00 umol/L	14 757 (34.12)	756 (29.18)	647 (31.29)	1085 (24.90)	
>14.00 umol/L	15 422 (35.65)	849 (32.76)	716 (34.62)	954 (21.87)	
BMI (%)					<.0001
<24 kg/m ²	17 638 (40.77)	780 (30.10)	622 (30.08)	1509 (34.62)	
24-28 kg/m ²	17 902 (41.38)	1108 (42.76)	842 (41.72)	1930 (44.28)	
>28 kg/m ²	7718 (17.85)	703 (27.13)	604 (29.20)	920 (21.10)	
Physical exercise (%)					<.0001
Never	3924 (9.07)	181 (6.99)	143 (6.92)	224 (5.14)	
Occasionally	32 406 (74.91)	1945 (75.07)	1518 (73.40)	2834 (65.01)	
Regularly	6928 (16.00)	465 (17.94)	407 (19.68)	1301 (29.85)	
Smoking status (%)					<.0001
Never	25 299 (58.49)	1404 (54.19)	1243 (60.11)	2446 (56.11)	
Past	2314 (5.35)	102 (3.94)	109 (5.27)	207 (4.75)	
Moderate	1676 (3.87)	92 (3.55)	57 (2.76)	119 (2.73)	
Severe	13 969 (32.29)	993 (38.32)	659 (31.86)	1587 (36.41)	

(Continues)

TABLE 1 (Continued)

Variables	Hs-CRP trajectory patterns				P-value
	Low-stable	Moderate-increasing	Increasing-decreasing	Elevated-decreasing	
Drinking status (%)					<.0001
Never	24 149 (55.83)	1479 (57.08)	1259 (60.88)	2558 (58.68)	
Past	1377 (3.18)	88 (3.40)	63 (3.05)	119 (2.73)	
Moderate	9606 (22.21)	458 (17.68)	321 (15.52)	598 (13.72)	
Severe	8126 (18.78)	566 (21.84)	425 (20.55)	1084 (24.87)	
Salt intake (%)					<.0001
Low (<6 g/day)	4198 (9.70)	202 (7.80)	156 (7.54)	269 (6.17)	
Intermediate (6-10 g/day)	33 879 (78.32)	1985 (76.61)	1589 (76.84)	2949 (67.65)	
High (>10 g/day)	5181 (11.98)	404 (15.59)	323 (15.62)	1141 (26.18)	
Sedentary lifestyle (%)					<.0001
<4 hours/day	31 346 (72.46)	1904 (73.49)	1490 (72.05)	2838 (65.11)	
4-8 hours/day	9981 (23.08)	443 (17.10)	393 (19.00)	574 (13.17)	
>8 hours/day	1931 (4.46)	244 (9.42)	185 (8.95)	947 (21.72)	
Hypertension (%)	15 917 (36.80)	1179 (45.50)	997 (48.21)	2124 (48.73)	<.0001
Diabetes mellitus (%)	2918 (6.75)	216 (8.34)	206 (9.96)	441 (10.12)	<.0001
Gallbladder polyp (%)	365 (0.84)	15 (0.58)	18 (0.87)	19 (0.44)	.1428
Gallstone disease (%)	851 (1.97)	73 (2.82)	59 (2.85)	100 (2.29)	<.0001
Fatty liver (%)	12 843 (29.69)	1056 (40.76)	848 (41.01)	1535 (35.21)	<.0001
Liver cirrhosis (%)	38 (0.09)	5 (0.19)	3 (0.15)	4 (0.09)	.2806
HBsAg seropositive (%)	1259 (2.91)	68 (2.62)	50 (2.42)	82 (1.88)	.0006
Family history of cancer (%)	1779 (4.11)	73 (2.82)	65 (3.14)	137 (3.14)	<.0001

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HBsAg, hepatitis B surface antigen; hs-CRP: high-sensitivity C-reactive protein; TBil, total bilirubin; TC, total cholesterol; TG, triglyceride; WC, waist circumference.

TABLE 2 Hazard ratios (HRs) for the association between hs-CRP trajectory patterns and overall cancer risk

Hs-CRP trajectory patterns	Cases/person-years	Crude models		Adjusted models	
		HR (95% CI)	P-value	HR (95% CI)	P-value
Low-stable pattern	1948/365 006	Ref.		Ref.	
Moderate-increasing pattern	210/21 527	1.65 (1.21-2.09)	<.0001	1.44 (1.19-1.69)	.0004
Increasing-decreasing pattern	154/17 422	1.53 (1.31-1.76)	<.0001	1.22 (1.04-1.41)	.0154
Elevated-decreasing pattern	198/35 924	1.11 (0.87-1.40)	.5301	1.07 (0.71-1.44)	.3172

Note: Adjusted models were adjusted for age (every 10 years), gender, BMI, TG, TC, TBil, ALT, diabetes, family income, educational background, marital status, salt consumption, current smoker, drinking status, physical activity, sedentary lifestyle and family history of cancer.

increasing-decreasing trajectory pattern were associated with an elevated risk of pooled cancers with the corresponding multivariate HR (95% CI) of 1.44 (1.19-1.69), 1.22 (1.04-1.41), respectively. However, no significant association between elevated-decreasing pattern and overall cancer risk after adjusting for potential confounders.

3.4 | Association of CRP trajectory patterns with the risk of specific-site cancer

Table 3 demonstrates the effect of CRP trajectories from 2006 to 2010 on the risk of specific-site cancer. In the site-specific analyses,

compared to the low-stable pattern of CRP, individuals in moderate-increasing trajectory pattern exhibited an increased risk of lung cancer (HR = 1.21, 95% CI: 1.04-1.42), breast cancer (HR = 1.30, 95% CI: 1.09-1.59), leukemia (HR = 9.54, 95% CI: 6.35-14.34), bladder cancer (HR = 1.31, 95% CI: 1.11-1.54), stomach cancer (HR = 1.22, 95% CI: 1.03-1.49), colorectal cancer (HR = 1.13, 95% CI: 1.01-1.23), liver cancer (HR = 1.07, 95% CI: 1.02-1.11) and gallbladder or extrahepatic bile duct cancer (HR = 1.33, 95% CI: 1.12-1.53) in the fully-adjusted analyses.

After adjusting for the aforementioned confounders, participants in the increasing-decreasing trajectory pattern were associated with an elevated risk of lung cancer (HR = 1.09, 95% CI: 1.02-1.15), breast

TABLE 3 Hazard ratios (HRs) for the association between hs-CRP trajectory patterns and specific site cancer risk

Specific cancer site	Cases	Hs-CRP trajectory patterns			
		Low-stable	Moderate-increasing	Increasing-decreasing	Elevated-decreasing
Lung cancer	664	Ref.	1.21 (1.04-1.42)	1.09 (1.02-1.15)	0.79 (0.61-1.02)
Breast cancer	202	Ref.	1.30 (1.09-1.59)	2.47 (1.16-2.51)	0.89 (0.51-1.56)
Leukemia	137	Ref.	9.54 (6.35-14.34)	0.93 (0.37-2.34)	4.87 (3.27-7.26)
Kidney cancer	141	Ref.	0.57 (0.23-1.39)	0.44 (0.15-1.72)	0.34 (0.15-1.77)
Bladder cancer	103	Ref.	1.31 (1.11-1.54)	6.71 (4.30-10.48)	0.72 (0.33-1.59)
Prostate cancer	80	Ref.	0.77 (0.28-2.11)	0.79 (0.29-2.19)	1.10 (0.30-1.45)
Pancreatic cancer	61	Ref.	0.86 (0.21-3.58)	1.92 (1.10-2.88)	0.43 (0.10-1.80)
Head and neck cancer	113	Ref.	0.84 (0.26-2.68)	0.37 (0.05-2.65)	1.04 (0.44-2.45)
Esophageal cancer	83	Ref.	0.62 (0.20-1.96)	1.30 (0.52-3.23)	0.23 (0.05-0.95)
Stomach cancer	161	Ref.	1.22 (1.03-1.49)	1.08 (0.52-2.21)	0.82 (0.46-1.47)
Colorectal cancer	348	Ref.	1.13 (1.01-1.23)	0.33 (0.15-0.73)	0.54 (0.35-0.85)
Liver cancer ^a	138	Ref.	1.07 (1.02-1.11)	1.29 (1.15-1.44)	0.88 (0.48-1.61)
Gallbladder or extrahepatic bile duct cancer ^b	63	Ref.	1.33 (1.12-1.53)	0.34 (0.05-2.44)	0.29 (0.07-1.23)

Note: Models were adjusted for age (every 10 years), gender, BMI, TG, TC, TBil, ALT, diabetes, family income, educational background, marital status, salt consumption, current smoker, drinking status, physical activity, sedentary lifestyle and family history of cancer.

Results presented with bold valued were statistically significant with all *p* value < 0.05.

^aFurther adjusted for HBV infection, liver cirrhosis and fatty liver disease.

^bFurther adjusted for gallstone disease and gallbladder polyp.

TABLE 4 Hazard ratios (HRs) for the association between hs-CRP trajectory patterns and specific site cancer risk in the sensitivity analysis

Group	Cases/person-years	Adjusted models	
		HR (95% CI)	P-value
Exclude participants hs-CRP > 10 mg/L			
Low-stable pattern	1948/365 006	Ref.	
Moderate-increasing pattern	178/14 999	1.86 (1.54-2.24)	<.0001
Increasing-decreasing pattern	131/11 627	1.84 (1.53-2.22)	<.0001
Elevated-decreasing pattern	156/27 284	1.02 (0.87-1.20)	.0532
Exclude participants who took aspirin			
Low-stable pattern	1927/363 222	Ref.	
Moderate-increasing pattern	210/21 423	1.44 (1.21-1.70)	<.0001
Increasing-decreasing pattern	154/17 310	1.42 (1.19-1.68)	.0001
Elevated-decreasing pattern	195/35 668	1.03 (0.70-1.42)	.2129
Exclude participants who took statins			
Low-stable pattern	1929/361 654	Ref.	
Moderate-increasing pattern	207/21 367	1.40 (1.17-1.65)	.0001
Increasing-decreasing pattern	151/17 214	1.38 (1.16-1.65)	.0003
Elevated-decreasing pattern	178/35 350	0.90 (0.77-1.04)	.1555
Exclude participants with follow-up < 1 year			
Low-stable pattern	1773/363 832	Ref.	
Moderate-increasing pattern	179/21 345	1.41 (1.16-1.64)	<.0001
Increasing-decreasing pattern	129/17 271	1.34 (1.11-1.58)	.0001
Elevated-decreasing pattern	150/35 662	0.94 (0.80-1.10)	.2331

Note: Models were adjusted for age (every 10 years), gender, BMI, TG, TC, TBil, ALT, diabetes, family income, educational background, marital status, salt consumption, current smoker, drinking status, physical activity, sedentary lifestyle and family history of cancer.

cancer (HR = 2.47, 95% CI: 1.16-2.51), bladder cancer (HR = 6.71, 95% CI: 4.30-10.48), pancreatic cancer (HR = 1.92, 95% CI: 1.10-2.88) and liver cancer (HR = 1.29, 95% CI: 1.15-1.44). Remarkably, the increasing-decreasing trajectory pattern was also associated with the decreased risk of colorectal cancer in the multivariate analyses (HR = 0.33, 95% CI: 0.15-0.73).

Compared to the low-stable pattern of CRP, individuals in the elevated-decreasing trajectory pattern had a 4.8-fold increased risk of leukemia in the adjusted models (HR = 4.87, 95% CI: 3.27 to 7.26). However, the elevated-decreasing trajectory pattern is also associated with decreased risk of esophageal cancer (HR = 0.23, 95% CI: 0.05 to 0.95) and colorectal cancer (HR = 0.54, 95% CI: 0.35 to 0.85).

3.5 | Sensitivity analysis

In the sensitivity analysis, after excluding individuals with CRP levels greater than 10 mg/L during 2006 to 2010 (n = 2601), or who had received oral aspirin therapy (n = 282), or who took statins (n = 535) at baseline examination, or with follow-up less than 1 year (n = 879), the association between CRP trajectory patterns and the risk of pooled cancers remained significant in the multivariate analysis (Table 4).

4 | DISCUSSION

In this large, prospective cohort study, compared to the low-stable CRP trajectory pattern within 4 years, we found (i) a positive association of the moderate-increasing CRP and increasing-decreasing CRP trajectory pattern with overall cancer risk; (ii) participants in the moderate-increasing CRP trajectory pattern exhibited elevated risk of lung, breast, bladder, stomach, colorectal, liver, gallbladder or extrahepatic bile duct cancer and leukemia; (iii) the increasing-decreasing CRP trajectory pattern was associated with increased risk of lung, breast, bladder, pancreatic, liver cancer and decreased risk of colorectal cancer. (iv) elevated-decreasing CRP trajectory pattern was associated with increased leukemia risk and decreased esophageal and colorectal cancer risk. As far as we are aware, this is the first study to comprehensively evaluate the impact of heterogeneous CRP trajectories on the risk of overall and specific-site cancers worldwide.

Participants in the moderate-increasing and increasing-decreasing CRP trajectory patterns were at a higher risk of developing cancer in the future. This should be a matter of concern for long-term management and control of CRP in clinical practice. Currently, no specific study has examined the effect of CRP changes on the risk of incident cancers. However, epidemiological studies have shown that elevated circulating CRP (single measurement) not only reflects the presence of cancer, but also is associated with an increased risk of cancer in the future for apparently healthy participants. A prospective study found that individuals with elevated CRP concentrations (>3 mg/L vs <1 mg/L) could expect a 1.3-fold and 2.2-fold increased risk of overall cancer and lung cancer, respectively, by analyzing 10 408 individuals

from the Danish general population.¹⁵ Wang et al observed 19 437 female participants from the Kailuan cohort study for up to 5 years who had baseline measurement of serum CRP, and found a respective 62% and 74% increased risk of overall and breast cancer for the highest CRP group (>3 mg/L) vs the lowest CRP group (<1 mg/L).²³ A nested case-control study of 592 lung cancer patients and 670 matched controls within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial reported that elevated CRP concentrations (highest quartile vs lowest quartile) were associated with a twofold increased risk of lung cancer risk.¹⁶ In a nested case-control study including 375 colorectal cancer (CRC) cases, Otani et al reported a 1.6-fold increased risk of CRC,²⁴ supported by similar results in a prospective cohort study by Allin et al.²⁵ Our previous study found a positive association between baseline CRP levels and the risk of primary liver cancer by analyzing 95 795 participants free of liver cancer.²⁶

Our results firstly demonstrate a close association between CRP trajectory patterns and elevated risk of leukemia and bladder cancer. However, no research has focused on the impact of CRP or CRP trajectories on the occurrence of leukemia or bladder cancer, making our study being the first to analyze this issue. According to research findings, extrinsic inflammatory factors contribute to the development of premalignant of leukemia.²⁷ Unlike PSA, CRP is neither a tumor-specific nor an organ-specific marker. Previous studies have shown that elevated CRP is an independent prognostic marker for survival of patients with urological malignancies,²⁸ which partly confirms our findings.

However, insignificant results were also observed in previous studies. Even though inflammatory bowel diseases are established risk factors of CRC, a prospective cohort study by Zhang et al failed to find a significant association between CRP levels and the risk of CRC among 27 913 healthy women during a 10-year follow-up. Results from a prospective study showed no association between CRP levels and risk of breast cancer.²⁹ Similarly, studies on the effect of serum CRP on the occurrence of prostate cancer have been mainly negative, including the largest to date nested case-control study involving 264 prostate cancer cases.^{30,31} This is somewhat unexpected, because prostatic inflammation is crucial for the etiology of prostate cancer.³²

It is worth noting that participants in the increasing-decreasing trajectory pattern and the elevated-decreasing pattern were associated with a reduced risk of esophageal or colorectal cancer. Individuals who experienced a reduction period in CRP levels exhibited a decreased risk of several cancers which was not reported in previous research. A randomized, double-blind, placebo-controlled trial found antiinflammatory therapy measured by CRP concentrations could significantly reduce the incidence and mortality of lung cancer by analyzing data of 10 061 myocardial infarction patients who were free of cancer.³³ An observational cohort study conducted by Klooster et al found that lifestyle improvements including smoking cessation, increase in physical activity and weight loss were related to a decrease in CRP concentration among cardiovascular disease patients.³⁴ In addition, results from a 2-year trial randomizing overweight or obese patients to a dietary regiment type found weight loss was the major

driver of lowering CRP concentration, regardless of diet composition.³⁵ In this current study, the reversed association between the decreased trajectory of CRP and cancer risk is independent of BMI. Taken together, the antiinflammatory effect produced by changing a healthy lifestyle and weight loss may partially clarify the anticancer effect of the decreasing trajectory of CRP in our study. Future studies should be conducted to better assess the potential mechanism of decline in serum CRP levels for the anticarcinogenesis effect.

Although the exact mechanisms surrounding the association of elevated CRP levels with increased risk of cancer remain unsolved, several possible mechanisms may help to elucidate this matter. Long-term low degree inflammation can promote tumor development and progression by leading to oxidation of protein and DNA.³⁶ Crucial pathways that maintain normal cellular homeostasis can be altered by genetic and epigenetic variations, due to mediators of the inflammatory response such as cytokines, free radicals, prostaglandins and growth factors. These variations include point mutations in tumor suppressor genes, DNA methylation and posttranslational variations, all of which can lead to the eventual presence and growth of cancer.³⁶ The association between inflammation and cancer has also been further fortified after observing the interaction of micro-RNAs and innate immunity during inflammation.³⁷ Previous research suggested that CRP was not just a marker of inflammation but has numerous critical proinflammatory properties.^{38,39} Specifically, CRP can cause the initiation of endothelial cells, monocytes and smooth muscle cells, prompt expression of adhesion molecules, chemo-attractant, tissue factors and activation of the NF- κ B pathway.⁴⁰ Adhesion molecule expression is essential for the invasion of cancer, whereas NF- κ B pathway activation has been linked to crucial oncogenic effects.

The major strength of this current study is that it provides a novel perception of the potential association between longitudinal CRP trajectory patterns and cancer risk. Furthermore, the broad evaluation of potential confounders has been well addressed in our study, including lifestyle behaviors and history of cancer-associated diseases. Finally, cancer cases were obtained through inspection of the Tangshan medical insurance system and the Kailuan social security system which record all the health information of participants. Using this method, the follow-up rate was almost 100% in the current study.

Limitations should also be noticed in our study when interpreting the results. First, the Kailuan study does not contain detailed information on other cancer-associated causal factors including hepatitis C virus (HBC) infection for liver cancer, and the consumption of cereal, vegetables and high-fiber food as well as *Helicobacter pylori* (Hp) infection for stomach cancer. The lack of details regarding the consumption of these foods hinders us from assessing confounding factors more precisely. However, the prevalence of hepatitis C core antibody is only 0.43% in China,⁴¹ dietary components are closely associated with BMI, and since serum biomarkers such as TC and TG⁴² have been taken into account, this may only have a small impact on the results. Second, the participants were all from the Kailuan community and were not nationally representative of the Chinese population. Thus, extrapolated results might

not be an accurate description of the wider Chinese population. Third, both moderate-increasing and increasing-decreasing trajectories were associated with an increased risk of several cancer types, however, the difference in meaning between moderate-increasing and increasing-decreasing trajectories in relation to cancer risk should be better elucidated in future epidemiological and experimental studies. Fourth, because of the close relationship between inflammation and cancer, a decrease in CRP levels should decrease the incidence of numerous cancer types. Whereas the antitumor effect was only observed in the esophagus and colorectal cancer, the mechanisms should be investigated in future studies.

5 | CONCLUSIONS

The results of our study have found that CRP trajectories play an important role in the occurrence of cancers, especially in the lung, breast, bladder, stomach, colorectal, liver, gallbladder or extrahepatic bile duct cancer and leukemia. The mechanism of anticarcinogenesis in the CRP decreasing trajectory pattern needs to be better elucidated in large cohort studies as well as experimental research in the future. We have also provided a novel method to explore the effect of CRP changes rather than a single CRP measurement in the prospective studies.

ACKNOWLEDGEMENTS

We thank all the staff and participants of the Kailuan study for their important contributions.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

All the work reported in the article has been performed by the authors unless clearly specified in the text. Tong Liu: Methodology, Software, Writing-Original draft preparation, Qingsong Zhang: Writing-Reviewing and Editing. Chunhua Song: Writing-Reviewing and Editing. Sarah Tan Siyin: Supervision, Validation. Shuhua Chen: Software. Qi Zhang: Writing-Reviewing and Editing. Mengmeng Song: Writing-Reviewing and Editing. Hanping Shi: Conceptualization, Supervision. Liying Cao: Conceptualization, Supervision, Validation, Resources.

DATA AVAILABILITY STATEMENT

Data will be made available upon reasonable request.

ETHICS STATEMENT

Our study was approved by the ethics committee of Kailuan General Hospital and followed the Declaration of Helsinki. Informed consent forms were signed by the participants or their legal representatives. Trial registration: Kailuan study, ChiCTR-TNRC-11001489. Registered 24 August, 2011-Retrospectively registered, <http://www.chictr.org.cn/showprojen.aspx?proj=8050>

ORCID

Mengmeng Song  <https://orcid.org/0000-0003-0258-3935>

Hanping Shi  <https://orcid.org/0000-0003-4514-8693>

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70(1):7-30.
- Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European cancer observatory. *Eur J Cancer.* 2015; 51(9):1164-1187.
- GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the global burden of disease study 2015. *Lancet.* 2016;388(10053):1659-1724.
- Alberg AJ, Shopland DR, Cummings KM. The 2014 surgeon general's report: commemorating the 50th anniversary of the 1964 report of the advisory committee to the US surgeon general and updating the evidence on the health consequences of cigarette smoking. *Am J Epidemiol.* 2014;179(4):403-412.
- Pflaum T, Hausler T, Baumung C, et al. Carcinogenic compounds in alcoholic beverages: an update. *Arch Toxicol.* 2016;90(10): 2349-2367.
- Whiteman DC, Wilson LF. The fractions of cancer attributable to modifiable factors: a global review. *Cancer Epidemiol.* 2016;44: 203-221.
- Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. *JAMA Oncol.* 2018;4(11):1553-1568.
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *Lancet Glob Health.* 2020;8(2):e180-e190.
- Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. *Cancer Epidemiol Biomarkers Prev.* 2005;14(8): 1847-1850.
- Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis.* 2009;30(7):1073-1081.
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature.* 2008;454(7203):436-444.
- Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem.* 2004; 279(47):48487-48490.
- Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest.* 2003;111(12):1805-1812.
- Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. *J Epidemiol Community Health.* 2007;61(9):824-833.
- Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol.* 2009;27(13):2217-2224.
- Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. *J Clin Oncol.* 2010;28(16):2719-2726.
- Liu T, Song C, Zhang Y, et al. Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study. *Int J Cancer.* 2021;150:1018-1028.
- Tanaka T, Okamura T, Miura K, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. *J Hum Hypertens.* 2002;16(2):97-103.
- He MM, Fang Z, Hang D, et al. Circulating liver function markers and colorectal cancer risk: a prospective cohort study in the UK biobank. *Int J Cancer.* 2021;148(8):1867-1878.
- Larsen IK, Myklebust T, Babigumira R, Vinberg E, Møller B, Ursin G. Education, income and risk of cancer: results from a Norwegian registry-based study. *Acta Oncol.* 2020;59(11):1300-1307.
- Sun D, Li H, Cao M, et al. Cancer burden in China: trends, risk factors and prevention. *Cancer Biol Med.* 2020;17(4):879-895.
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin.* 2016;66(2):115-132.
- Wang G, Li N, Chang S, et al. A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan female cohort. *Cancer Epidemiol Biomarkers Prev.* 2015;24(2):459-465.
- Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. *Cancer Epidemiol Biomarkers Prev.* 2006;15(4):690-695.
- Allin KH, Bojesen SE, Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. *Int J Cancer.* 2016;139(7):1493-1500.
- Siyin ST, Liu T, Li W, et al. A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer. *BMC Cancer.* 2020;20(1):1168.
- Sjövall D, Staffas A. The origin of leukemia: genetic alterations and inflammatory factors in the development of premalignant clonal hematopoiesis. *Semin Hematol.* 2020;57(1):7-12.
- Köhler A, Eggers H, Kuczyk MA, Schrader AJ, Steffens S. Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies. *Aktuelle Urol.* 2013;44(6): 452-455.
- Zhang SM, Lin J, Cook NR, et al. C-reactive protein and risk of breast cancer. *J Natl Cancer Inst.* 2007;99(11):890-894.
- Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. *J Clin Oncol.* 2006;24(33):5216-5222.
- Platz EA, De Marzo AM, Erlinger TP, et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. *Prostate.* 2004;59(4): 393-400.
- De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. *Nat Rev Cancer.* 2007;7(4):256-269.
- Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet.* 2017; 390(10105):1833-1842.
- van't Klooster CC, van der Graaf Y, Ridker PM, et al. The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. *Atherosclerosis.* 2020;301:37-43.
- Nicklas JM, Sacks FM, Smith SR, et al. Effect of dietary composition of weight loss diets on high-sensitivity c-reactive protein: the randomized POUNDS LOST trial. *Obesity (Silver Spring).* 2013;21(4): 681-689.
- Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. *Int J Cancer.* 2007;121(11):2373-2380.
- Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer.* 2006;6(4):259-269.
- Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation.* 2000; 102(18):2165-2168.

